Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with solid tumour(s)~* Anaemia (hgb less than or equal to 11.0 g/dL~* Planned to receive cyclic chemotherapy~* At least 6-month life expectancy~* Eastern Cooperative Oncology Group (ECOG) status of 0 to 2~* Adequate renal and liver function~* At least 18 years of age~Exclusion Criteria:~* Central nervous system disease~* Iron deficiency~* Received more than 2 RBC transfusions within 4 weeks before randomisation or any RBC transfusion within 2 weeks before randomisation~* Received recombinant human erythropoietin (rHuEPO) therapy within 8 weeks before randomisation~* History of any seizure disorder~* Cardiac disease~* Active infection or inflammatory disease~* Known positive test for HIV infection~* Known primary haematologic disorder which could cause anaemia~* Use of other investigational agent(s)/device(s)~* Pregnant or breast feeding~* Known hypersensitivity to any recombinant mammalian derived product

- Gender: None
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NESP - Schedule 1 Part A (Type: EXPERIMENTAL): Part A - 4.5, 6.75, 9.0 or 13.5 mcg/kg Q3W for 12 weeks
- NESP - Schedule 2 Part A (Type: EXPERIMENTAL): NESP 9.0, 12.0, 15.0 or 18.0 mcg/kg Q4W for 12 weeks
- Placebo - Schedule 1 Part A (Type: PLACEBO_COMPARATOR): Placebo Q3W for 12 weeks
- NESP - Schedule 1 Part B (Type: EXPERIMENTAL): Open-label NESP at the dose of study drug administered at the end of Part A. Increase dose at week 19 if hgb \< 13.0g/dL and/or RBC transfusion in previous 2 weeks.
- Placebo - Schedule 2 Part A (Type: PLACEBO_COMPARATOR): Placebo Q4W for 12 weeks
- NESP - Schedule 2 Part B (Type: EXPERIMENTAL): Open-label NESP at the dose of study drug administered at the end of Part A

Based on this trial design, predict the completion outcome and termination type (if applicable).